GlassScriptPhysician profile
Leandre Michael Millet
NPI 1952989725
$721.47
in general payments reported to CMS, 2019-2025
12 companies · $499 in 2025
The $499 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.92 · 2024: $192 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.20 | 2022-2025 | Fasenra |
| Mallinckrodt Hospital Products INC. | $110.10 | 2025 | Acthar, Terlivaz |
| Amgen INC. | $65.87 | 2022-2025 | Tavneos |
| Akebia Therapeutics INC | $52.70 | 2025 | Vafseo |
| Travere Therapeutics, INC. | $38.50 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $35.62 | 2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.07 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.50 | 2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $24.01 | 2024 | |
| Aurinia Pharma U.S., INC. | $23.09 | 2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $18.17 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandre Millet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.